Milestone Pharmaceuticals Announces Cardamyst Study Plan
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 10 2026
0mins
Should l Buy MIST?
Milestone Pharmaceuticals announced details on RESET-PSVT, a planned Phase 4, multicenter, prospective, observational registry intended to generate real-world evidence on the use of Cardamyst nasal spray in adults with paroxysmal supraventricular tachycardia. "Registry of Etripamil Studies Evaluating Treatment in Paroxysmal Supraventricular Tachycardia: Study Design," was presented in a poster session at the Preventive Cardiovascular Nurses Association Cardiovascular Nursing Symposium in Scottsdale, Arizona. The study will be led by the Duke Clinical Research Institute. RESET-PSVT is expected to enroll an estimated 450 adult patients across approximately 20 electrophysiology and cardiology sites, with enrollment beginning by the end of 2026. The registry is designed to evaluate patients who have been prescribed Cardamyst as well as patients prescribed or given other therapies, with enrolled patients and their healthcare providers completing patient- and provider-outcome surveys, respectively. The study's primary endpoint is to characterize patterns of use of Cardamyst in PSVT management, including frequency of PSVT episodes, frequency of use of Cardamyst, number of doses administered per episode and triggers for use. Secondary endpoints include comparisons between Cardamyst and non-Cardamyst users across patient-reported quality of life, healthcare utilization and episode characteristics. Exploratory analyses are expected to evaluate prescribing and use patterns across patient subgroups, along with qualitative analysis of participant experience.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MIST?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MIST
Wall Street analysts forecast MIST stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 2.100
Low
8.00
Averages
8.00
High
8.00
Current: 2.100
Low
8.00
Averages
8.00
High
8.00
About MIST
Milestone Pharmaceuticals Inc. is a Canada-based biopharmaceutical company. The Company is focused on the development and commercialization of cardiovascular medicines. Its lead product candidate, etripamil, is a potent rapid-onset calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by patients. The Company is also focused on developing etripamil to treat paroxysmal supraventricular tachycardia, atrial fibrillation, and other cardiovascular indications.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Milestone Pharmaceuticals Launches CARDAMYST Registry Study
- Study Design Unveiled: Milestone Pharmaceuticals presented the RESET-PSVT study design at the 2026 Cardiovascular Nursing Symposium, aiming to generate real-world evidence on CARDAMYST (etripamil) in patients with paroxysmal supraventricular tachycardia (PSVT), with an estimated enrollment of 450 patients across approximately 20 electrophysiology and cardiology sites.
- Clinical Application Expansion: The RESET-PSVT study will evaluate usage patterns of CARDAMYST, including PSVT episode frequency and medication usage, aiming to deepen understanding of patient quality of life and healthcare utilization in routine care, thereby supporting future scientific dialogue with robust data.
- Patient Feedback Collection: The study will collect patient-reported outcomes through surveys from both patients and healthcare providers, helping researchers better understand the practical application of CARDAMYST in PSVT management, and is expected to provide critical clinical insights for healthcare providers.
- Future Results Sharing: Results from the study are anticipated to be shared at future scientific conferences and in peer-reviewed publications, further enhancing the recognition of CARDAMYST's value in acute PSVT management, marking the first registry of its kind in this field.
See More
Milestone Pharmaceuticals Reports Q4 and FY 2025 Results with CARDAMYST Updates
- Financial Performance: Milestone Pharmaceuticals reported a wider net loss of $17.4 million for Q4 2025, translating to $0.16 per share, compared to a loss of $12.4 million or $0.19 per share in the previous year, indicating financial pressures during the product launch phase.
- Revenue Source: The company recorded $1.54 million in revenue for Q4 2025 from a milestone payment under its licensing agreement with Corxel Pharmaceuticals, marking an initial success in the commercialization of CARDAMYST following its FDA approval in the U.S.
- Product Approval and Marketing: CARDAMYST received FDA approval in December 2025 as the first self-administered nasal spray, with a sales team of 60 representatives expected to enhance market penetration in the cardiology sector.
- Future Plans: Milestone plans to conduct a Phase 3 registrational program to evaluate Etripamil for acute atrial fibrillation control, intending to leverage the initial PSVT indication to facilitate subsequent regulatory approvals.
See More
Milestone Pharmaceuticals Earnings Report Preview
- Earnings Release Date: Milestone Pharmaceuticals is expected to release its earnings report on March 19, indicating a significant focus from the market on the company's future performance and potential stock movements.
- Earnings Per Share Forecast: Analysts predict an earnings per share of 16 cents, reflecting the company's profitability in the current market environment, which could influence shareholder confidence and investment decisions.
- Revenue Expectations: The company is anticipated to generate $1.20 million in revenue, suggesting Milestone's efforts in product promotion and market acceptance, which may lay the groundwork for future growth opportunities.
- Market Reaction Anticipation: Following the earnings report, investors will closely monitor the actual results against analyst expectations, which will directly impact Milestone Pharmaceuticals' stock price volatility and overall market sentiment.
See More
Milestone Pharmaceuticals Reports Q4 2025 Earnings and CARDAMYST Launch
- Revenue and Loss Overview: Milestone Pharmaceuticals reported milestone revenue of $1.5 million in Q4 2025, yet faced a net loss of $63.1 million for the year, translating to a loss of $0.75 per share, highlighting financial pressures during the early market launch phase.
- CARDAMYST Launch Progress: The company successfully launched CARDAMYST within six weeks of FDA approval, with over 150 prescriptions filled by more than 100 unique prescribers in the first month, indicating a positive initial market reception for the drug.
- Financial Position and Future Outlook: As of December 31, 2025, Milestone had $106 million in cash and cash equivalents, and with approximately $200 million in pro forma cash raised post-year-end, the company is well-positioned for operations into late 2027, enhancing its competitive stance in the market.
- Insurance Coverage Challenges: Despite positive feedback for CARDAMYST, the company faces significant delays in insurance coverage, with over half of prescriptions not being filled due to insurer controls, and Medicare coverage is not expected until 2027, which may hinder market penetration.
See More
Milestone Pharmaceuticals Reports FY Results
- Earnings Report: Milestone Pharmaceuticals reported a FY GAAP EPS of -$0.75, indicating significant challenges in profitability that could undermine investor confidence.
- Revenue Figures: The company generated revenue of $1.55 million, which, while providing some income, falls short of market expectations, potentially putting downward pressure on the stock price.
- Market Reaction: Analysts downgraded Milestone to a 'Sell' rating as CARDAMYST faces tough market realities, which may further influence investor sentiment towards the company.
- Investor Sentiment: Following the approval of Cardamyst, the market's negative reaction suggests that selling news related to Milestone may not be prudent, potentially leading to increased stock price volatility in the short term.
See More
Major Earnings Reports Expected on Friday
- Earnings Reports: Major companies set to report earnings on Friday include Milestone Pharmaceuticals (MIST), Westwater Resources (WWR), and XPeng (XPEV), which will provide investors with crucial financial data and market outlooks.
- Market Focus: Investors will closely monitor these earnings reports to assess performance and future growth potential, particularly in the current economic climate where market sensitivity to tech and resource companies is heightened.
- Industry Impact: XPeng, as an electric vehicle manufacturer, will have its earnings report scrutinized for its potential influence on the overall EV sector, possibly affecting investor confidence and capital flows within the industry.
- Investor Strategy: With the earnings season approaching, investors may adjust their strategies in response to the upcoming performance data, particularly reevaluating positions in companies that have underperformed in the market.
See More
Milestone Pharmaceuticals Launches CARDAMYST Registry Study
- Study Design Unveiled: Milestone Pharmaceuticals presented the RESET-PSVT study design at the 2026 Cardiovascular Nursing Symposium, aiming to generate real-world evidence on CARDAMYST (etripamil) in patients with paroxysmal supraventricular tachycardia (PSVT), with an estimated enrollment of 450 patients across approximately 20 electrophysiology and cardiology sites.
- Clinical Application Expansion: The RESET-PSVT study will evaluate usage patterns of CARDAMYST, including PSVT episode frequency and medication usage, aiming to deepen understanding of patient quality of life and healthcare utilization in routine care, thereby supporting future scientific dialogue with robust data.
- Patient Feedback Collection: The study will collect patient-reported outcomes through surveys from both patients and healthcare providers, helping researchers better understand the practical application of CARDAMYST in PSVT management, and is expected to provide critical clinical insights for healthcare providers.
- Future Results Sharing: Results from the study are anticipated to be shared at future scientific conferences and in peer-reviewed publications, further enhancing the recognition of CARDAMYST's value in acute PSVT management, marking the first registry of its kind in this field.
See More
Milestone Pharmaceuticals Reports Q4 and FY 2025 Results with CARDAMYST Updates
- Financial Performance: Milestone Pharmaceuticals reported a wider net loss of $17.4 million for Q4 2025, translating to $0.16 per share, compared to a loss of $12.4 million or $0.19 per share in the previous year, indicating financial pressures during the product launch phase.
- Revenue Source: The company recorded $1.54 million in revenue for Q4 2025 from a milestone payment under its licensing agreement with Corxel Pharmaceuticals, marking an initial success in the commercialization of CARDAMYST following its FDA approval in the U.S.
- Product Approval and Marketing: CARDAMYST received FDA approval in December 2025 as the first self-administered nasal spray, with a sales team of 60 representatives expected to enhance market penetration in the cardiology sector.
- Future Plans: Milestone plans to conduct a Phase 3 registrational program to evaluate Etripamil for acute atrial fibrillation control, intending to leverage the initial PSVT indication to facilitate subsequent regulatory approvals.
See More
Milestone Pharmaceuticals Earnings Report Preview
- Earnings Release Date: Milestone Pharmaceuticals is expected to release its earnings report on March 19, indicating a significant focus from the market on the company's future performance and potential stock movements.
- Earnings Per Share Forecast: Analysts predict an earnings per share of 16 cents, reflecting the company's profitability in the current market environment, which could influence shareholder confidence and investment decisions.
- Revenue Expectations: The company is anticipated to generate $1.20 million in revenue, suggesting Milestone's efforts in product promotion and market acceptance, which may lay the groundwork for future growth opportunities.
- Market Reaction Anticipation: Following the earnings report, investors will closely monitor the actual results against analyst expectations, which will directly impact Milestone Pharmaceuticals' stock price volatility and overall market sentiment.
See More
Milestone Pharmaceuticals Reports Q4 2025 Earnings and CARDAMYST Launch
- Revenue and Loss Overview: Milestone Pharmaceuticals reported milestone revenue of $1.5 million in Q4 2025, yet faced a net loss of $63.1 million for the year, translating to a loss of $0.75 per share, highlighting financial pressures during the early market launch phase.
- CARDAMYST Launch Progress: The company successfully launched CARDAMYST within six weeks of FDA approval, with over 150 prescriptions filled by more than 100 unique prescribers in the first month, indicating a positive initial market reception for the drug.
- Financial Position and Future Outlook: As of December 31, 2025, Milestone had $106 million in cash and cash equivalents, and with approximately $200 million in pro forma cash raised post-year-end, the company is well-positioned for operations into late 2027, enhancing its competitive stance in the market.
- Insurance Coverage Challenges: Despite positive feedback for CARDAMYST, the company faces significant delays in insurance coverage, with over half of prescriptions not being filled due to insurer controls, and Medicare coverage is not expected until 2027, which may hinder market penetration.
See More
Milestone Pharmaceuticals Reports FY Results
- Earnings Report: Milestone Pharmaceuticals reported a FY GAAP EPS of -$0.75, indicating significant challenges in profitability that could undermine investor confidence.
- Revenue Figures: The company generated revenue of $1.55 million, which, while providing some income, falls short of market expectations, potentially putting downward pressure on the stock price.
- Market Reaction: Analysts downgraded Milestone to a 'Sell' rating as CARDAMYST faces tough market realities, which may further influence investor sentiment towards the company.
- Investor Sentiment: Following the approval of Cardamyst, the market's negative reaction suggests that selling news related to Milestone may not be prudent, potentially leading to increased stock price volatility in the short term.
See More
Major Earnings Reports Expected on Friday
- Earnings Reports: Major companies set to report earnings on Friday include Milestone Pharmaceuticals (MIST), Westwater Resources (WWR), and XPeng (XPEV), which will provide investors with crucial financial data and market outlooks.
- Market Focus: Investors will closely monitor these earnings reports to assess performance and future growth potential, particularly in the current economic climate where market sensitivity to tech and resource companies is heightened.
- Industry Impact: XPeng, as an electric vehicle manufacturer, will have its earnings report scrutinized for its potential influence on the overall EV sector, possibly affecting investor confidence and capital flows within the industry.
- Investor Strategy: With the earnings season approaching, investors may adjust their strategies in response to the upcoming performance data, particularly reevaluating positions in companies that have underperformed in the market.
See More
